Categories: News

Cyberliver Announces Poster Presentation of AlcoChange, Pilot Study at The Liver Meeting 2018

Cyberliver reports a positive pilot study of AlcoChange, a patented Smartphone Tool and Behavioural Intervention Platform to Reduce Alcohol Consumption in Alcohol-Related Liver Disease. The data from this study is very exciting and shows that we can potentially find new treatments using digital technologies for treating liver disease to reduce deaths and improve quality of life.

London, United Kingdom, November 12, 2018 –(PR.com)– Cyberliver Ltd., a developer of cutting edge solutions for liver care, today announced that Dr Gautam Mehta and team will present a poster at The Liver Meeting 2018 of the American Association for the Study of Liver Diseases held on Friday, November 9th through Tuesday, November 13th, at the Moscone North and South Convention Centre in San Francisco.

The poster is entitled: “AlcoChange: A Pilot Study of a Smartphone Tool to Reduce Alcohol Consumption in Alcohol-Related Liver Disease (Poster #1398)” will be presented on Sunday, November 11 2018, between 8:00 AM and 5:30 PM at Hall C – Poster Hall.

Dr. Gautam Mehta, Clinical Lead of the study, Consultant and Senior Lecturer in Hepatology at Royal Free Hospital said, “We are delighted to be presenting this study at The Liver Meeting 2018. The data demonstrate the potential of digital tools like AlcoChange to help manage alcohol-related liver disease (ARLD).” The AlcoChange clinical study, which ran from spring 2015 to end of 2017 at Royal Free London NHS Trust, supported by The Health Foundation and led by Prof. Kevin Moore and Dr. Gautam Mehta, clearly demonstrated that a smartphone app/breathalyzer can be used for self-monitoring and for Behavior Change Interventions (BCIs) in patients with ARLD, with a clear “dose response” amongst compliant patients. “Smartphone apps are a scalable intervention to help maintain abstinence in ARLD.”

Commenting on the study, Prof. Rajiv Jalan, Clinician Scientist, Prof. of Hepatology, Head of Liver Failure group at UCL said, “The data from this study is very exciting and shows that we can potentially find new treatments using digital technologies for treating liver disease to reduce deaths and improve quality of life.”

About Cyberliver:
Cyberliver is a company that focuses on delivering cutting edge solutions for liver care via use of innovative technology, based out of London, England, UK.

About AlcoChange:
AlcoChange is a patented Smartphone App/Breathalyzer platform, allows the monitoring of craving, alcohol consumption and breath alcohol, and provides motivational messaging in response to patient triggers.

For AlcoChange and Cyberliver Contact:
Ravi Kumar, ravi.kumar@Cyberliver.com
First Floor, Burnells, 5 Garland Road, Stanmore, Middlesex, HA7 1NR, United Kingdom

Let’s block ads! (Why?)

Miscw.com

Recent Posts

Inside the battle over Kerala PSC: a recruitment scandal becomes a constitutional showdown

The real battle over the Kerala PSC isn't just about who cheated on an exam;…

20 minutes ago

Xiaomi and Samsung Expand Flip Lines as Washington Prepares for Leadership Reshuffle

Xiaomi has launched its next-generation foldable and its first flip Android phone, the Xiaomi Mix…

49 minutes ago

Google Launches Gemini Omni 1.2 Flash as Chatbot Faces Lawsuit in California

Google has officially launched Gemini Omni 1.2 Flash in general availability across Google Cloud and…

1 hour ago

HDFC Bank share price extends winning streak, up 12% from 52-week low

Three-day rally takes HDFC Bank shares 12% off the bottomHDFC Bank shares rose for a…

2 hours ago

Telangana CEO faces pressure over unpaid poll bills and 82% voter backlog

The Telangana CEO is facing pressure on two election-administration fronts at once. Deputy collectors want…

2 hours ago

PFC Shares Rise 2% on Rs 4.10 Interim Dividend; PFC-REC Merger Scheme Cleared at 88:100 Swap

Power Finance Corporation shares rose about 2% after the board declared a second interim dividend…

3 hours ago